NICE backs Novartis’ Cosentyx for underdiagnosed back conditionNICE has extended the range of indications that Novartis’ Cosentyx can be prescribed for by the NHS in Share XNICE backs Novartis’ Cosentyx for underdiagnosed back conditionhttps://pharmaphorum.com/news/nice-backs-novartis-cosentyx-for-underdiagnosed-back-condition/
Alvotech files lawsuit challenging AbbVie’s Humira patent thicketBiosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira Share XAlvotech files lawsuit challenging AbbVie’s Humira patent thickethttps://pharmaphorum.com/news/alvotech-files-lawsuit-challenging-abbvies-humira-patent-thicket/
Sanofi licences in potential oral IL-17 drug from UK’s C4X DiscoverySanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal Share XSanofi licences in potential oral IL-17 drug from UK’s C4X Discoveryhttps://pharmaphorum.com/news/sanofi-licences-in-potential-oral-il-17-drug-from-uks-c4x-discovery/
Amgen buys inflammatory diseases drug firm Rodeo for up to $721mAmgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its Share XAmgen buys inflammatory diseases drug firm Rodeo for up to $721mhttps://pharmaphorum.com/news/acquisitive-amgen-buys-inflammatory-diseases-drug-firm-rodeo-for-up-to-721m/
Lilly’s mirikuzumab hits target in phase 3 ulcerative colitis trialA phase 3 trial of Lilly’s inflammatory diseases challenger mirikizumab in ulcerative colitis has met its target – Share XLilly’s mirikuzumab hits target in phase 3 ulcerative colitis trialhttps://pharmaphorum.com/news/lillys-mirikuzumab-hits-target-in-phase-3-ulcerative-colitis-trial/
BMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitisBristol-Myers Squibb’s commercial hopes for new multiple sclerosis drug Zeposia have yet to bear fruit thanks to the Share XBMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitishttps://pharmaphorum.com/news/bms-eyes-may-fda-verdict-for-ms-drug-zeposia-in-ulcerative-colitis/
GSK suffers another R&D setback, axing ulcerative colitis drug trialGlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in Share XGSK suffers another R&D setback, axing ulcerative colitis drug trialhttps://pharmaphorum.com/news/gsk-suffers-another-rd-setback-axing-ulcerative-colitis-drug-trial/
AbbVie scores crucial phase 3 wins with Humira follow-up SkyriziAbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms Share XAbbVie scores crucial phase 3 wins with Humira follow-up Skyrizihttps://pharmaphorum.com/news/abbvie-scores-crucial-phase-3-wins-with-humira-follow-up-skyrizi/
Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypsSanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps Share XSanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypshttps://pharmaphorum.com/news/dupixent-on-notice-as-fda-reviews-gsks-nucala-for-nasal-polyps/
